<SEC-DOCUMENT>0000950170-24-131712.txt : 20241129 <SEC-HEADER>0000950170-24-131712.hdr.sgml : 20241129 <ACCEPTANCE-DATETIME>20241129091559 ACCESSION NUMBER: 0000950170-24-131712 CONFORMED SUBMISSION TYPE: 144 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20241129 DATE AS OF CHANGE: 20241129 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Candel Therapeutics, Inc. CENTRAL INDEX KEY: 0001841387 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 522214851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 144 SEC ACT: 1933 Act SEC FILE NUMBER: 001-40629 FILM NUMBER: 241513436 BUSINESS ADDRESS: STREET 1: 117 KENDRICK STREET STREET 2: SUITE 450 CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: 617-916-5445 MAIL ADDRESS: STREET 1: 117 KENDRICK STREET STREET 2: SUITE 450 CITY: NEEDHAM STATE: MA ZIP: 02494 FORMER COMPANY: FORMER CONFORMED NAME: Candel Therapeutics, Inic. DATE OF NAME CHANGE: 20210120 REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: Tak Paul Peter CENTRAL INDEX KEY: 0001873905 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 144 MAIL ADDRESS: STREET 1: CANDEL THERAPEUTICS, INC. STREET 2: 117 KENDRICK ST SUITE 450 CITY: NEEDHAM STATE: MA ZIP: 02494 </SEC-HEADER> <DOCUMENT> <TYPE>144 <SEQUENCE>1 <FILENAME>primary_doc.xml <TEXT> <XML> <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"> <headerData> <submissionType>144</submissionType> <filerInfo> <filer> <filerCredentials> <cik>0001873905</cik> <ccc>XXXXXXXX</ccc> </filerCredentials> </filer> <liveTestFlag>LIVE</liveTestFlag> </filerInfo> </headerData> <formData> <issuerInfo> <issuerCik>0001841387</issuerCik> <issuerName>CANDEL THERAPEUTICS, INC.</issuerName> <secFileNumber>001-40629</secFileNumber> <issuerAddress> <street1 xmlns="http://www.sec.gov/edgar/common">117 Kendrick St</street1> <street2 xmlns="http://www.sec.gov/edgar/common">Suite 450</street2> <city xmlns="http://www.sec.gov/edgar/common">Needham</city> <stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry> <zipCode xmlns="http://www.sec.gov/edgar/common">02494</zipCode> </issuerAddress> <issuerContactPhone>617-916-5445</issuerContactPhone> <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Tak Paul Peter</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold> <relationshipsToIssuer> <relationshipToIssuer>Officer</relationshipToIssuer> <relationshipToIssuer>Director</relationshipToIssuer> </relationshipsToIssuer> </issuerInfo> <securitiesInformation> <securitiesClassTitle>Common Stock</securitiesClassTitle> <brokerOrMarketmakerDetails> <name>Morgan Stanley Smith Barney</name> <address> <street1 xmlns="http://www.sec.gov/edgar/common">2000 Westchester Ave</street1> <city xmlns="http://www.sec.gov/edgar/common">Purchase</city> <stateOrCountry xmlns="http://www.sec.gov/edgar/common">NY</stateOrCountry> <zipCode xmlns="http://www.sec.gov/edgar/common">10577-2530</zipCode> </address> </brokerOrMarketmakerDetails> <noOfUnitsSold>44433</noOfUnitsSold> <aggregateMarketValue>219943.35</aggregateMarketValue> <noOfUnitsOutstanding>32475537</noOfUnitsOutstanding> <approxSaleDate>11/29/2024</approxSaleDate> <securitiesExchangeName>NASDAQ</securitiesExchangeName> </securitiesInformation> <securitiesToBeSold> <securitiesClassTitle>Common Stock</securitiesClassTitle> <acquiredDate>11/28/2022</acquiredDate> <natureOfAcquisitionTransaction>RSU Award</natureOfAcquisitionTransaction> <nameOfPersonfromWhomAcquired>Candel Therapeutics, Inc.</nameOfPersonfromWhomAcquired> <isGiftTransaction>N</isGiftTransaction> <amountOfSecuritiesAcquired>44433</amountOfSecuritiesAcquired> <paymentDate>11/28/2022</paymentDate> <natureOfPayment>Not Applicable</natureOfPayment> </securitiesToBeSold> <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months> <remarks>The sales reported on this Form 144 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person.</remarks> <noticeSignature> <noticeDate>11/29/2024</noticeDate> <signature>/s/ Charles Schoch, as Attorney-in-Fact for Paul Peter Tak</signature> </noticeSignature> </formData> </edgarSubmission> </XML> </TEXT> </DOCUMENT> </SEC-DOCUMENT>